Response to: Correspondence on “Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure” by Yalta <i>et al</i>
Journal: Heart
Year: 2021

The Authors’ reply 

We would like to thank Yalta et al 1 for their interest in our review. We share their enthusiasm for the potential metabolic benefits of sodium-glucose co-transporter 2 (SGLT-2) inhibition.

We agree with Yalta et al that in patients with type 2 diabetes or heart failure, there is dysregulated fatty acid oxidation and impaired glucose uptake causing myocardial dysfunction. In this setting of restricted fuel selection and low energetic reserve, ketone bodies are a super-fuel